

## Yale Cancer Center ASCO Participation – 2018 Annual Meeting

### Oral Abstract Sessions

**Friday, June 1; 4:21 PM to 4:33 PM**

**Location: S404**

*State breast density inform mandate laws and utilization of adjunctive screening tests and cancer detection following screening mammography.*

**Cary Gross**

**Monday, June 4; 5:24 PM to 5:36 PM**

**Location: Arie Crown Theater**

*Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.*

**Charles Fuchs**

**Tuesday, June 5; 8:24 AM to 8:36 AM**

**Location: S406**

*Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.*

**Brian Henick**

### Education Sessions

**Friday, June 1; 4:30 PM to 4:50 PM**

**Location: S100a**

*Why Do We Care About Molecular Evolution in Breast Cancer?*

**Lajos Pusztai**

## **Poster Sessions**

**Saturday, June 2; 8:00 AM to 11:30 AM**

**Location:** Hall A

*Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.*

**Xiaotong Li**

**Saturday, June 2; 1:15 PM to 4:45 PM**

**Location:** Hall A

*Changes in access to care and financial hardship associated with Affordable Care Act (ACA) implementation for cancer survivors aged 19-64 years.*

**Amy Davidoff**

*Development of a dashboard for end-of-life care at an academic hospital.*

**Kerin Adelson**

*Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.*

**Scott Huntington**

*Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.*

**Sarah Goldberg**

*Breast Cancer Risk Perception and Adherence to U.S. Cancer Prevention Guidelines.*

**Jillian Eckroate**

**Sunday, June 3; 8:00 AM to 11:30 AM**

**Location:** Hall A

*Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).*

**Stacey Stein**

*Differential outcomes in patients with uncommon EGFR exon 19 mutations.*

**Tyler Stewart**

*Insurance disparity in cause-specific mortalities: A SEER study on early stage, non-elderly NSCLC cancer survivors.*

**Changchuan Jiang**

*NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.*

**Michael Cecchini**

*Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.*

**Allison Campbell**

**Monday, June 4; 8:00 AM - 11:30 AM**

**Location:** Hall A

*Establishment of a medical student elective on the oncology consult service using the seven principles of teaching.*

**Hari Deshpande**

**Monday, June 4; 1:15 PM to 4:45 PM**

**Location:** Hall A

*Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.*

**Thuy Tran**

*Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.*

**Roy S. Herbst**

*Patterns and determinants of pain and emotional distress in older adults with cancer: A population based study.*

**Amy Davidoff**

*A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.*

**Alessandro Santin**

*Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).*

**Ila Datar**